Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-14
1997-01-28
Acquah, Samuel A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514247, 514256, 514303, 514319, 514357, 514428, 514429, 514647, 514657, 514811, A01N 4360, A61K 31495
Patent
active
055978266
ABSTRACT:
The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.
REFERENCES:
patent: 4940731 (1990-07-01), Bick
patent: 4962128 (1990-10-01), Doogan et al.
patent: 5130338 (1992-07-01), Bacopoulos
CA (116): 128,683.
CA (118): 169,115.
CA (111): 77800.
Luciana Giardino, "Modulation of GABAergic System by the SSRI Sertraline", Neuropsychopharmacology, vol. 10, No. 3S/P, p. 6S, May 1994.
Pierre Blier and Claude de Montigney, "Current Advances and Trends in the Treatment of Depression", Trends in Pharmacological Sciences, vol. 15, No. 7, p. , (Jul. 1994).
Patrick Martin and Alain J. Puech, "Is there a relationship between 5-HT.sub.1B receptors and the mechanisms of action of antidepressant drugs in the learned helplessness paradigm in rats?", European Journal of Pharmacology, 192 (1991) 193-196.
B. Kenneth Koe, et al., "Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of .beta.-adrenoceptor system of rat brain", European Journal of Pharmacology, 141 (1987) 187-194.
Mike Briley and Chantal Moret, "Neurobiological Mechanisms Involved in Antidepressant Therapies", Clinical Neuropharmacology, vol. 16, No. 5, pp. 387-400 (1993).
Chenard Bertrand L.
Howard Harry R.
Macor John E.
Schulz David W.
Sprouse Jeffrey S.
Acquah Samuel A.
Butterfield Garth
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Compositions containing sertraline and a 5-HT.sub.1D receptor ag does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions containing sertraline and a 5-HT.sub.1D receptor ag, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions containing sertraline and a 5-HT.sub.1D receptor ag will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-941674